Traders should monitor for any upcoming earnings releases or clinical trial updates that may have prompted the timing of these sales. While equity grants are routine, the concentrated selling by multiple top executives raises caution, especially if not part of a pre-arranged 10b5-1 plan. Check future Form 4s to determine if selling continues.
Price Chart
Executive Summary
Multiple C-suite executives at Aquestive Therapeutics (AQST) sold shares in the open market, with the CFO, COO, and Chief Commercial Officer collectively selling $500K worth of stock. These sales coincide with a routine grant of equity awards to executives, which include both time-based and performance-based shares at zero cost, valued at $781K on grant date but representing non-cash compensation.
Key Financial Metrics
Key Facts
- CFO, COO, and Chief Commercial Officer sold a combined $500K in open-market transactions at $4.173 per share.
- All sales occurred on March 10, 2026, indicating coordinated timing.
- On March 9, 2026, multiple C-suite executives received stock awards totaling 507,500 shares, with $781K in value attributed to shares awarded at $4.29 (likely the closing price that day).
- The majority of awarded shares (382,500) were granted at $0, indicating they are likely performance-based or time-vested with no immediate economic value.
- Total open-market insider selling represents ~0.1% of AQST's $513M market cap, which is modest but notable given the concentration among top executives.
Financial Impact
$500,000 in net open-market selling by C-suite executives; $781,000 in new equity grants with non-cash value
Risk Factors
- Perception of insider lack of confidence due to coordinated C-suite selling.
- Potential for increased share supply if more insiders follow suit.
- Performance-based grants may lead to future dilution if targets are met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (13 trades, 7d window) | cluster-AQST-1773247908624 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 15, 2026 11d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 14, 2026 12d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $3.97 (−13.88%) |
Oct 7, 2026 19d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $3.97 (−14.07%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $3.97 (+14.07%) |
Sep 29, 2026 27d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $3.97 (−14.99%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $3.97 (−15.17%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $3.97 (−14.81%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $3.97 (−17.63%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $3.97 (−7.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers